OTC:CLSDQ
Clearside Biomedical, Inc.
A clinical-stage biotech firm advancing proprietary antibody therapies for rare liver diseases with a focus on AATD.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock for speculative upside if the company successfully secures major licensing deals or achieves breakthrough clinical trial results in its alpha-1 antitrypsin deficiency pipeline. The proprietary antibody platform offers a unique technological edge that could lead to significant value creation upon product commercialization and regulatory approval.
Bear Case
The stock carries extreme downside risk given the massive accumulated deficit of -$355.3M and current cash position of only $20.0M against long-term liabilities exceeding $59M. With revenues fluctuating between $1.3M and $8.2M over the last three years and consistent annual losses, the company lacks a clear path to profitability without substantial external funding.
About Clearside Biomedical, Inc.
Clearside Biomedical (CLSDQ) is a clinical-stage biotechnology company focused on developing novel therapeutics for liver disease, specifically targeting alpha-1 antitrypsin deficiency. The company leverages its proprietary platform to create high-affinity antibodies and aims to address significant unmet medical needs in hepatology markets.
Analysis
Management Discussion
Recent financial performance highlights a severe cash burn rate driven by $18.6M in research and development expenses and $11.8M in general and administrative costs against minimal revenue of $1.7M. While the company managed to raise $16.4M from financing activities, its operating profit remains deeply negative at -$28.9M, indicating that current business models are not yet self-sustaining.
Industry Overview
The liver disease therapeutics market is highly competitive with large pharmaceutical incumbents dominating approved treatments, creating high barriers to entry for smaller biotech firms. Regulatory pathways for rare diseases like AATD are stringent, requiring extensive clinical data that can drain the resources of early-stage companies quickly. The industry is characterized by a 'valley of death' between late-stage development and commercial launch where many promising assets fail.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.3M | $8.2M | $1.7M |
| Cost of Revenue | $0 | $355.0K | $149.0K |
| Gross Profit | $1.3M | $7.9M | $1.5M |
| Operating Expenses | $31.6M | $33.1M | $30.4M |
| Operating Income | $-30.3M | $-24.8M | $-28.9M |
| R&D | $19.6M | $20.8M | $18.6M |
| G&A | $11.8M | $11.9M | $11.8M |
| Stock-Based Comp | $4.9M | $4.2M | $4.5M |
| Depreciation | $145.0K | $67.0K | $226.0K |
| Other OpEx | $204.0K | $355.0K | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | — | — | $1.5M |
| Pre-Tax Income | $-30.3M | $-24.8M | $-28.9M |
| Income Tax | $2.7M | $7.6M | $5.5M |
| Continuing Ops | $-32.9M | $-32.5M | $-34.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-32.9M | $-32.5M | $-34.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-32.9M | $-32.5M | $-34.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $49.4M | $30.1M | $21.3M |
| Cash & Equivalents | $48.3M | $28.9M | $20.0M |
| Accounts Receivable | $0 | $170.0K | $507.0K |
| Other Current Assets | $1.1M | $1.0M | $747.0K |
| Long-Term Assets | $1.9M | $3.9M | $3.9M |
| PP&E (Net) | $755.0K | $3.0M | $3.2M |
| Operating Leases | $1.1M | $869.0K | $597.0K |
| Other LT Assets | $30.0K | $30.0K | $30.0K |
| Total Assets | $51.3M | $34.0M | $25.1M |
| Current Liabilities | $5.8M | $6.8M | $4.8M |
| Accounts Payable | $1.1M | $2.2M | $1.5M |
| Current Leases | $349.0K | $364.0K | $375.0K |
| Other Current Liab | $205.0K | $75.0K | $0 |
| Long-Term Liabilities | $34.9M | $43.1M | $59.2M |
| LT Operating Leases | $936.0K | $649.0K | $328.0K |
| Other LT Liab | $34.0M | $42.5M | $58.9M |
| Total Liabilities | $40.7M | $49.9M | $64.0M |
| Shareholders' Equity | $10.6M | $-15.9M | $-38.9M |
| Paid-In Capital | $299.0M | $304.9M | $316.3M |
| Retained Earnings | $-288.4M | $-320.9M | $-355.3M |
| Total L&E | $51.3M | $34.0M | $25.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-32.9M | $-32.5M | $-34.4M |
| Non-Cash Adjustments | $28.7M | $14.1M | $11.0M |
| Working Capital Changes | $-9.2M | $248.0K | $-1.3M |
| Cash from Operations | $-13.4M | $-18.1M | $-24.7M |
| Capital Expenditures | $246.0K | $1.8M | $977.0K |
| Cash from Investing | $-246.0K | $-1.8M | $-638.0K |
| Debt Issuances | $0 | — | — |
| Debt Repayments | $0 | — | — |
| Cash from Financing | $31.3M | $414.0K | $16.4M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $17.7M | $-19.5M | $-8.9M |
| Beginning Cash | $30.7M | $48.4M | $28.9M |
| Ending Cash | $48.4M | $28.9M | $20.0M |
Frequently Asked Questions
How does Clearside Biomedical, Inc. make money?
The company's primary revenue stream consists of product development services and licensing agreements, evidenced by recent revenues of $1.7M despite heavy R&D spend. Revenue generation relies heavily on milestone payments from partners for its pipeline assets rather than commercial sales of approved drugs at this stage.
What are the main risks for CLSDQ?
The company faces significant cash burn risks with a net loss of $34.4M and a negative change in cash of $8.9M, raising concerns about capital sufficiency. There is substantial dilution risk as the company has accumulated a retained earnings deficit of -$355.3M and relies on paid-in capital to fund operations. Regulatory approval risks are high given the clinical-stage nature of its pipeline with no currently approved products generating commercial revenue.
What is CLSDQ's competitive advantage?
Clearside possesses a proprietary platform technology for generating high-affinity antibodies that offer superior binding characteristics compared to conventional methods. The company holds multiple patents protecting its core discovery and development technologies in the liver disease space. Its deep expertise in hepatology provides a specialized knowledge moat against generalist biotechnology competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.